NASDAQ : IOVA
Iovance Biotherapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 9.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of 324.97M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 324.97M | 263.50M | 164.07M | 1.19M | ||
| Cost of Revenue | 167.68M | 173.18M | 93.25M | 1.03M | ||
| Gross Profit | 157.29M | 90.32M | 70.82M | 156.00K | ||
| Selling, General & Admin | 149.18M | 152.32M | 152.27M | 106.10M | 104.10M | 83.66M |
| Research & Development | 267.71M | 300.27M | 276.23M | 333.19M | 294.78M | 259.04M |
| Operating Expenses | 453.45M | 488.53M | 466.10M | 460.71M | 398.88M | 342.70M |
| Operating Income | -296.17M | -398.21M | -395.28M | -460.56M | -398.88M | -342.70M |
| Interest & Investment Income | 1.95M | 3.10M | 4.51M | 9.44M | 3.46M | 6.46M |
| EBT Excluding Unusual Items | -294.22M | -395.11M | -390.77M | -451.12M | -395.42M | -336.24M |
| Merger & Restructuring Charges | -5.14M | -5.14M | ||||
| Gain (Loss) on Sale of Investments | 5.59M | 7.20M | 10.26M | 3.60M | -474.00K | -6.01M |
| Other Unusual Items | 5.50M | |||||
| Pretax Income | -293.78M | -393.05M | -375.00M | -447.52M | -395.89M | -342.25M |
| Income Tax Expense | -4.26M | -2.07M | -2.83M | -3.48M | ||
| Net Income | -289.52M | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M |
| Net Income to Common | -289.52M | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M |
| Shares Outstanding (Basic) | 410.20M | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M |
| Shares Outstanding (Diluted) | 410.20M | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M |
| EPS (Basic) | -0.71 | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS (Diluted) | -0.71 | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| Free Cash Flow | -296.39M | -336.24M | -364.05M | -384.11M | -313.18M | -265.51M |
| Free Cash Flow Per Share | -0.72 | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 |
| Gross Margin | 48.40% | 34.28% | 43.17% | 13.12% | ||
| Operating Margin | -91.14% | -151.12% | -240.92% | -38,734.99% | ||
| Profit Margin | -89.09% | -148.38% | -226.84% | -37,345.42% | ||
| Free Cash Flow Margin | -91.21% | -127.61% | -221.89% | -32,305.30% | ||
| EBITDA | -259.60M | -362.27M | -357.64M | -439.14M | -389.57M | -339.59M |
| EBITDA Margin | -79.88% | -137.48% | -217.98% | |||
| D&A For EBITDA | 36.56M | 35.94M | 37.63M | 21.42M | 9.31M | 3.11M |
| EBIT | -296.17M | -398.21M | -395.28M | -460.56M | -398.88M | -342.70M |
| EBIT Margin | -91.14% | -151.12% | -240.92% | |||
| Revenue as Reported | 324.97M | 263.50M | 164.07M | 1.19M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 110.77M | 163.08M | 115.69M | 114.89M | 231.73M | 78.23M |
| Short-Term Investments | 186.91M | 133.90M | 208.09M | 164.98M | 240.11M | 426.18M |
| Cash & Short-Term Investments | 297.67M | 296.98M | 323.78M | 279.87M | 471.85M | 504.41M |
| Receivables | 102.12M | 82.45M | 69.34M | 151.00K | ||
| Inventory | 55.59M | 51.68M | 51.52M | 10.37M | ||
| Prepaid Expenses | 8.87M | 11.58M | 12.38M | 17.46M | 7.27M | 3.55M |
| Total Current Assets | 464.26M | 442.69M | 457.02M | 307.85M | 479.12M | 507.96M |
| Property, Plant & Equipment | 174.94M | 177.01M | 164.28M | 176.54M | 178.25M | 169.92M |
| Long-Term Investments | 91.59M | |||||
| Other Intangible Assets | 263.89M | 279.32M | 282.40M | 229.26M | ||
| Other Long-Term Assets | 12.44M | 14.15M | 6.73M | 66.70M | 6.62M | 7.87M |
| Total Assets | 915.53M | 913.17M | 910.43M | 780.35M | 663.98M | 777.33M |
| Accounts Payable | 26.21M | 22.16M | 27.51M | 33.12M | 26.60M | 27.38M |
| Accrued Expenses | 74.62M | 104.71M | 75.19M | 66.97M | 45.78M | 51.91M |
| Current Portion of Long-Term Debt | 1.00M | |||||
| Current Portion of Leases | 2.67M | 4.04M | 12.90M | 7.78M | 12.59M | 5.06M |
| Other Current Liabilities | 3.35M | 6.45M | 6.75M | 2.44M | 6.51M | 4.86M |
| Total Current Liabilities | 106.85M | 138.36M | 122.34M | 110.31M | 91.48M | 89.20M |
| Long-Term Debt | 1.00M | 1.00M | 1.00M | 1.00M | ||
| Long-Term Leases | 43.33M | 44.40M | 44.37M | 67.08M | 71.86M | 65.47M |
| Long-Term Deferred Tax Liabilities | 29.31M | 31.83M | 32.31M | 17.35M | ||
| Total Liabilities | 179.49M | 214.59M | 200.02M | 195.74M | 164.34M | 155.67M |
| Common Stock | 19.00K | 17.00K | 13.00K | 11.00K | 8.00K | 7.00K |
| Additional Paid-In Capital | 3.62B | 3.46B | 3.10B | 2.59B | 2.07B | 1.79B |
| Retained Earnings | -2.90B | -2.78B | -2.38B | -2.01B | -1.57B | -1.17B |
| Comprehensive Income & Other | 13.08M | 16.44M | -1.05M | 2.53M | -902.00K | -601.00K |
| Total Common Equity | 736.04M | 698.58M | 710.40M | 584.61M | 499.63M | 621.66M |
| Shareholders' Equity | 736.04M | 698.58M | 710.40M | 584.61M | 499.64M | 621.66M |
| Total Liabilities & Equity | 915.53M | 913.17M | 910.43M | 780.35M | 663.98M | 777.33M |
| Total Debt | 46.00M | 49.44M | 58.26M | 75.86M | 85.45M | 71.53M |
| Net Cash (Debt) | 251.67M | 247.54M | 265.52M | 204.00M | 386.40M | 432.88M |
| Net Cash Per Share | 0.61 | 0.69 | 0.92 | 0.87 | 2.43 | 2.82 |
| Filing Date Shares Outstanding | 452.97M | 411.96M | 327.88M | 279.31M | 224.24M | 157.17M |
| Total Common Shares Outstanding | 452.97M | 411.94M | 305.25M | 256.14M | 187.81M | 157.00M |
| Working Capital | 357.41M | 304.33M | 334.68M | 197.54M | 387.63M | 418.76M |
| Book Value Per Share | 1.62 | 1.70 | 2.33 | 2.28 | 2.66 | 3.96 |
| Tangible Book Value | 472.15M | 419.26M | 428.00M | 355.35M | 499.63M | 621.66M |
| Tangible Book Value Per Share | 1.04 | 1.02 | 1.40 | 1.39 | 2.66 | 3.96 |
| Machinery | 44.89M | 45.34M | 34.28M | 33.27M | 31.79M | 14.87M |
| Construction In Progress | 5.56M | 35.65M | 34.94M | 24.10M | 9.12M | 35.78M |
| Leasehold Improvements | 128.89M | 90.39M | 67.38M | 76.80M | 74.31M | 57.82M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -289.52M | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M |
| Depreciation & Amortization | 44.98M | 47.32M | 48.07M | 33.13M | 21.14M | 13.98M |
| Loss (Gain) From Sale of Assets | 670.00K | 44.00K | 1.79M | |||
| Asset Writedown & Restructuring Costs | 397.00K | |||||
| Loss (Gain) From Sale of Investments | -5.59M | -7.20M | -10.26M | -3.60M | 474.00K | 6.01M |
| Stock-Based Compensation | 46.72M | 61.58M | 109.63M | 62.62M | 84.02M | 69.77M |
| Other Operating Activities | 2.94M | 11.10M | -3.00M | -3.41M | ||
| Change in Accounts Receivable | -42.18M | -13.11M | -69.19M | -149.00K | ||
| Change in Inventory | -12.13M | -14.21M | -44.38M | -10.12M | ||
| Change in Accounts Payable | -5.54M | -6.66M | -7.84M | 4.83M | 5.88M | 6.98M |
| Change in Other Net Operating Assets | -4.54M | 9.71M | -5.61M | -1.08M | -8.78M | 17.58M |
| Operating Cash Flow | -264.18M | -302.41M | -352.98M | -361.82M | -292.76M | -227.94M |
| Capital Expenditures | -32.21M | -33.84M | -11.07M | -22.29M | -20.43M | -37.57M |
| Cash Acquisitions | -52.57M | -212.63M | ||||
| Investment in Securities | -12.66M | 81.33M | -32.77M | 79.68M | 276.88M | 37.71M |
| Investing Cash Flow | -44.87M | 47.50M | -96.41M | -155.24M | 256.45M | 132.00K |
| Long-Term Debt Issued | 1.00M | |||||
| Net Debt Issued (Repaid) | 1.00M | |||||
| Issuance of Common Stock | 294.11M | 307.83M | 403.52M | 465.75M | 192.80M | 238.27M |
| Repurchase of Common Stock | -6.26M | -7.06M | -12.86M | -2.79M | -2.65M | |
| Financing Cash Flow | 287.85M | 300.77M | 390.66M | 462.96M | 190.15M | 239.27M |
| Foreign Exchange Rate Adjustments | -440.00K | 1.14M | -541.00K | -2.74M | ||
| Net Cash Flow | -21.64M | 47.01M | -59.27M | -56.84M | 153.85M | 11.46M |
| Free Cash Flow | -296.39M | -336.24M | -364.05M | -384.11M | -313.18M | -265.51M |
| Free Cash Flow Margin | -91.21% | -127.61% | -221.89% | -32,305.30% | ||
| Free Cash Flow Per Share | -0.72 | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 |
| Levered Free Cash Flow | -187.79M | -162.42M | -198.76M | -211.47M | -173.54M | -129.35M |
| Unlevered Free Cash Flow | -187.79M | -162.42M | -198.76M | -211.47M | -173.54M | -129.35M |
| Change in Working Capital | -64.39M | -24.27M | -127.02M | -6.52M | -2.89M | 24.55M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.59B | 1.08B | 2.26B | 2.08B | 1.01B | 3.00B |
| Enterprise Value | 3.34B | 835.41M | 1.94B | 1.80B | 728.55M | 2.49B |
| Last Close Price | 8.48 | 2.73 | 7.40 | 8.13 | 6.39 | 19.09 |
| PS Ratio | 11.07 | 4.11 | 13.75 | 1,749.89 | ||
| PB Ratio | 5.22 | 1.55 | 3.17 | 3.56 | 2.02 | 4.82 |
| P/TBV Ratio | 7.62 | 2.58 | 5.27 | 5.86 | 2.02 | 4.82 |
| EV/Sales Ratio | 10.30 | 3.17 | 11.80 | 1,512.80 | ||
| Debt / Equity Ratio | 0.06 | 0.07 | 0.08 | 0.13 | 0.17 | 0.12 |
| Net Debt / Equity Ratio | -0.34 | -0.35 | -0.37 | -0.35 | -0.77 | -0.70 |
| Net Debt / EBITDA Ratio | 0.97 | 0.68 | 0.74 | 0.47 | 0.99 | 1.27 |
| Net Debt / FCF Ratio | 0.85 | 0.74 | 0.73 | 0.53 | 1.23 | 1.63 |
| Asset Turnover | 0.36 | 0.29 | 0.19 | 0.00 | ||
| Inventory Turnover | 3.18 | 3.36 | 3.01 | |||
| Quick Ratio | 3.74 | 2.74 | 3.21 | 2.54 | 5.16 | 5.66 |
| Current Ratio | 4.34 | 3.20 | 3.74 | 2.79 | 5.24 | 5.70 |
| Return on Equity (ROE) | -40.36% | -55.50% | -57.48% | -81.91% | -70.61% | -53.55% |
| Return on Assets (ROA) | -20.31% | -27.30% | -29.22% | -39.86% | -34.59% | -27.71% |
| Return on Capital Employed (ROCE) | -36.60% | -51.40% | -50.20% | -68.70% | -69.70% | -49.80% |
| Earnings Yield | -8.91% | -36.08% | -16.50% | -21.34% | -39.25% | -11.43% |
| FCF Yield | -8.24% | -31.03% | -16.14% | -18.46% | -31.05% | -8.87% |
| Buyback Yield / Dilution | -29.62% | -23.28% | -23.28% | -47.64% | -3.82% | -10.92% |